More recently, a direct comparison trial between crenolanib and midostaurin in combination with standard chemotherapy started to be explored within a clinical trial enrolling newly-diagnosed FLT3-mutant AML (NCT03258931). This evidence concerns the gene FLT3 and acute myeloid leukemia.